DCGI approves AstraZeneca Dapagliflozin for heart failure treatment in adults
New Delhi: AstraZeneca Pharma India Ltd., a science-led biopharmaceutical company, announced it has received extended indication approval from the Drugs Controller General of India (DCGI) for its drug, Dapagliflozin in the treatment of heart failure (HF) in adults.
The approval is based on the detailed results from the DELIVER Phase III trial—the largest and broadest HF trial to date in patients with LVEF (left ventricular ejection fraction) >40%. AstraZeneca’s original research product dapagliflozin significantly reduced the composite of cardiovascular (CV) death or worsening heart failure in patients with HF with mildly reduced or preserved ejection fraction (EF), compared to placebo. The results were consistent across pre-defined subgroups.
Dapagliflozin is already approved for HF with reduced ejection fraction. The additional indication will expand the indication for all types of HF irrespective of ejection fraction. Dapagliflozin is the only SGLT-2i which has shown mortality benefits in the pooled analysis of heart failure across LVEF.
Heart failure is a chronic, progressive disease impacting nearly 64 million people globally and about 10 million in India, which comprises of both heart failure with preserved ejection fraction and reduced ejection fraction. The available data from Indian HF registries show that HF patients in India are younger by 10-years, and the majority of the burden lies below 65 years of age, as compared to the patients from high-income countries.
Read also: Sanofi-AstraZeneca Beyfortus gets USFDA nod for protection of infants against RSV disease
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.